There are several advantages to having multiple non-mRNA-based COVID-19 vaccines.
CNBC’s Meg Tirrell talks with Johnson & Johnson chief scientific officer Dr. Paul Stoffels on the company’s coronavirus vaccine trials. Johnson & Johnson announced Wednesday its early-stage human trial for a potential coronavirus vaccine will begin in the second half…